178 results on '"Voog E"'
Search Results
2. Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.
3. AVENANCE : efficacité et tolérance en vie réelle d'avelumab en traitement d'entretien de première ligne (1LM) chez les patients atteints d'un carcinome urothélial avancé (aUC) et analyse exploratoire des traitements...
4. 1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
5. 1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
6. 1991P Subgroup analyses of patients (pts) with advanced urothelial carcinoma (aUC) who had long-term progression-free survival (PFS) or overall survival (OS) with avelumab first-line maintenance (1LM) in the AVENANCE real-world study
7. 1975P Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
8. 1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
9. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial
10. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
11. Minor clone provides a reservoir for relapse in multiple myeloma
12. 603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial
13. 2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
14. 1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2
15. 1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
16. 1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
17. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial
18. Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone
19. 704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
20. 659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2
21. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial
22. Results of a phase II randomized trial of docetaxel (D), Estramustine (E) and prednisone (P)—two schedules—versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC)
23. PCR detection of Epstein-Barr virus, herpes simplex virus and human papillomavirus from the anal mucosa in HIV-seropositive and HIV-seronegative homosexual men
24. Genomic profiling of patients with metastatic castration-resistant prostate cancer (mCRPC) for the evaluation of rucaparib: Next-generation sequencing (NGS) of tumour tissue and cell-free DNA (cfDNA)
25. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
26. CARFILZOMIB WEEKLY PLUS MELPHALAN AND PREDNISONE IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA (IFM 2012-03) / 21st Congress of the European-Hematology-Association
27. Série de radiothérapie en conditions stéréotaxiques de métastases cérébrales précédée ou non d’une irradiation panencéphalique dite prophylactique
28. Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial
29. Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study
30. 362 - Genomic profiling of patients with metastatic castration-resistant prostate cancer (mCRPC) for the evaluation of rucaparib: Next-generation sequencing (NGS) of tumour tissue and cell-free DNA (cfDNA)
31. Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone
32. 2621 Everolimus in advanced urothelial carcinoma (UC) pretreated with at least 2 lines of chemotherapy (CT) the afinivest study
33. Hypertension artérielle rénovasculaire révélant un synovialosarcome
34. The Treatment (Tx) of Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: A Systematic Literature Review and Network Meta-Analysis
35. 784O - Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial
36. Minor clone provides a reservoir for relapse in multiple myeloma
37. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients
38. Supériorité confirmée de l’association melphalan-prednisone–thalidomide (MP–T) chez des patients de plus de 75 ans avec un myélome multiple (MM) de novo : protocole IFM 01/01, MP–T versus MP en double insu versus placebo
39. Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study
40. A Multicenter Prospective Randomized Study Testing Non-Inferiority of Thalidomide 100 mg/day as Compared with 400 mg/day in Patients with Refractory/Relapsed Multiple Myeloma: First Results of the Final Analysis of the IFM 01-02 Study.
41. Late Onset, Acute Severe Neutropenia in Patients Treated with Rituximab for B-Cell Lymphoproliferation.
42. Multicenter Phase II Feasibility Trial of High-Dose Tamoxifen in Patients With Refractory or Relapsed Multiple Myeloma
43. Phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) — Two schedules — versus mitoxantrone (M) and prednisone in patients (PTS) with hormone refractory prostate cancer (HRPC)
44. Ovarian cancer
45. Multicentric Phase II Study of Cisplatin and Etoposide in Patients With Metastatic Carcinoma of Unknown Primary
46. A Prospective Study Of The LMB Regimen For Diffuse Large Cell Non Hodgkin's Lymphoma In Adults
47. OP10. Integrating patients' preferences in therapeutic decisions in cancer: Development of a decision board
48. Demonstration of Epstein-Barr Virus DNA in Acetowhite Lesions of the Vulva
49. The prevalence of "high-risk" HPV types in penile condyloma-like lesions: correlation between HPV type and morphology.
50. Follow-up of men with genital papilloma virus infection. Psychosexual aspects.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.